Literature DB >> 3536082

Histochemical studies with an estrogen receptor-related protein in human breast tumors.

A Cano, A I Coffer, R Adatia, R R Millis, R D Rubens, R J King.   

Abstract

The histochemical characteristics of a Mr 29,000 phosphoprotein related to estradiol receptor are described in a large series of human breast tumors. The antigen was detected with a monoclonal antibody (D5) raised against partially purified human myometrial estradiol receptor. An indirect immunoperoxidase method was used with methacarn-fixed, wax-embedded sections. Quantitation of staining and its reproducibility are described. Results with trucut biopsies agree with those obtained with larger tumor sections. Normal breast is infrequently positive. Histochemical staining is higher in invasive carcinoma than in normal breast with ductal carcinoma in situ adjacent to infiltrating tumors exhibiting intermediate values. Furthermore, most in situ carcinomas have a heterogeneous staining pattern. About 20% of invasive tumors also exhibit heterogeneity. No simple correlation is seen between staining and histological grade. There are more low-staining tumors in young (less than 50 yr old) patients than in older women. Staining correlates with levels of cytosol estradiol receptor but not cytosol progesterone receptor. However, cytosol estradiol receptor-negative, cytosol progesterone receptor-positive tumors tend to have positive Mr 29,000 phosphoprotein levels. Positive staining is associated with a higher response rate to hormone therapy (50%). None of the negative tumors responded to hormone treatment. With these patients, comparison of histochemical assay for Mr 29,000 phosphoprotein and [3H]estradiol binding assays indicated that the former was at least as good as the latter assay in predicting hormone response. About 20% of cytosol estradiol receptor-positive tumors have low Mr 29,000 phosphoprotein, and such tumors have poor response to hormone treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3536082

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Immunological evidence for the identity between the hsp27 estrogen-regulated heat shock protein and the p29 estrogen receptor-associated protein in breast and endometrial cancer.

Authors:  D R Ciocca; E H Luque
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

2.  Differential expression of oestrogen receptor and oestrogen inducible genes in gastric mucosa and cancer.

Authors:  S Singh; R Poulsom; N A Wright; M C Sheppard; M J Langman
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

3.  Effects of estrogens on the testis of transsexuals: a pathological and immunocytochemical study.

Authors:  A Sapino; A Pagani; A Godano; G Bussolati
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

Review 4.  Oestrogen and colonic epithelial cell growth.

Authors:  S Singh; M J Langman
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

5.  Differential expression of steroid receptors, hsp27, and pS2 in a series of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or to fractionated X-irradiation.

Authors:  R D Whelan; B T Hill
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

6.  Immunohistology of oestrogen receptor and D5 antigen in breast cancer: correlation with oestrogen receptor content of adjacent cryostat sections assayed by radioligand binding and enzyme immunoassay.

Authors:  D D Giri; V J Dangerfield; R Lonsdale; K Rogers; J C Underwood
Journal:  J Clin Pathol       Date:  1987-07       Impact factor: 3.411

Review 7.  William L. McGuire Memorial Symposium. Estrogen and progestin effects in human breast carcinogenesis.

Authors:  R J King
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

8.  Immunohistochemical study of D5 antigen (an oestrogen receptor related protein) in normal breast, benign breast disease, and mammary carcinoma in situ.

Authors:  A Girling; M Caleffi; R J King; R R Millis
Journal:  J Clin Pathol       Date:  1988-04       Impact factor: 3.411

9.  Response of breast carcinoma to endocrine therapy predicted using immunostained pelleted fine needle aspirates.

Authors:  E Heyderman; S R Ebbs; S E Larkin; B M Brown; A M Haines; T Bates
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

10.  A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer.

Authors:  S Love; R J King
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.